Perrigo Company plc Cash and Cash Equivalents, Period Increase (Decrease)
Perrigo Company plc (PRGO) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$127.60 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-27
- Perrigo Company plc cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $106.90M.
- Perrigo Company plc cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-29 was -$82.30M, a 645.03% decline year-over-year.
- Perrigo Company plc cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$160.80M.
- Perrigo Company plc cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $8.60M, a 99.65% decline year-over-year.
- Perrigo Company plc cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$127.60M, a 326.24% decline from fiscal 2017.
- Perrigo Company plc cash and cash equivalents, period increase (decrease) for fiscal 2017 was $56.40M, a 72.42% decline from fiscal 2016.
- Perrigo Company plc cash and cash equivalents, period increase (decrease) for fiscal 2016 was $204.50M.
- Perrigo Company plc cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$13.90M, a 170.92% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | $106.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $24.60M derived: sum of 2 quarters · filed 2019-02-27 | -$136.20M derived: sum of 3 quarters · filed 2019-02-27 | -$127.60M 10-K · filed 2019-02-27 | |
| 2018-09-29 | -$82.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$243.10M derived: sum of 2 quarters · filed 2018-11-08 | -$234.50M 10-Q · filed 2018-11-08 | -$331.70M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2018-06-30 | -$160.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$152.20M 10-Q · filed 2018-08-09 | -$249.40M derived: sum of 3 quarters · filed 2019-02-27 | -$234.30M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2018-03-31 | $8.60M 10-Q · filed 2018-05-08 | -$88.60M derived: sum of 2 quarters · filed 2019-02-27 | -$73.50M derived: sum of 3 quarters · filed 2019-02-27 | -$2.39B derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-12-31 | -$97.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$82.10M derived: sum of 2 quarters · filed 2019-02-27 | -$2.40B derived: sum of 3 quarters · filed 2019-02-27 | $56.40M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $15.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$2.30B derived: sum of 2 quarters · filed 2018-11-08 | $153.60M 10-Q · filed 2018-11-08 | $413.20M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-07-01 | -$2.32B derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $138.50M 10-Q · filed 2018-08-09 | $398.10M derived: sum of 3 quarters · filed 2019-02-27 | $119.00M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-04-01 | $2.46B 10-Q · filed 2018-05-08 | $2.72B derived: sum of 2 quarters · filed 2019-02-27 | $2.44B derived: sum of 3 quarters · filed 2019-02-27 | $2.49B derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $259.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$19.50M derived: sum of 2 quarters · filed 2019-02-27 | $33.40M derived: sum of 3 quarters · filed 2019-02-27 | $204.50M 10-K · filed 2019-02-27 | |
| 2016-10-01 | -$279.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$226.20M derived: sum of 2 quarters · filed 2017-11-09 | -$55.10M 10-Q · filed 2017-11-09 | -$143.80M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-07-02 | $52.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $224.00M 10-Q · filed 2017-08-10 | $135.30M derived: sum of 3 quarters · filed 2018-03-01 | -$143.80M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-04-02 | $171.10M 10-Q · filed 2017-05-30 | $82.40M derived: sum of 2 quarters · filed 2018-03-01 | -$196.70M derived: sum of 3 quarters · filed 2018-03-01 | -$2.84B derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | -$88.70M derived: 10-K 6 month − 10-Q 3 month · filed 2018-03-01 | -$367.80M 10-K · filed 2018-03-01 | -$3.01B derived: sum of 3 quarters · filed 2018-03-01 | -$3.18B derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-09-26 | -$279.10M 10-Q · filed 2015-11-02 | -$2.92B derived: sum of 2 quarters · filed 2017-05-22 | -$3.09B 10-Q/A · filed 2017-05-23 | -$385.00M derived: sum of 4 quarters · filed 2017-05-22 | |
| 2015-06-27 | -$2.64B derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | -$2.81B 10-Q/A · filed 2017-05-22 | -$105.90M derived: sum of 3 quarters · filed 2017-05-22 | -$13.90M 10-K · filed 2018-03-01 | |
| 2015-03-28 | -$165.70M 10-Q/A · filed 2017-05-22 | $2.54B derived: sum of 2 quarters · filed 2017-05-22 | $2.63B 10-Q · filed 2015-04-29 | $2.82B derived: sum of 4 quarters · filed 2017-05-22 | |
| 2014-12-27 | $2.70B derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-05 | $2.80B 10-Q · filed 2015-02-05 | $2.99B derived: sum of 3 quarters · filed 2017-05-22 | $3.08B derived: sum of 4 quarters · filed 2017-05-22 | |
| 2014-09-27 | $92.00M 10-Q · filed 2015-11-02 | $282.10M derived: sum of 2 quarters · filed 2017-05-22 | $370.40M derived: sum of 3 quarters · filed 2017-05-22 | $74.90M derived: sum of 4 quarters · filed 2017-05-22 | |
| 2014-06-28 | $190.10M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $278.40M derived: sum of 2 quarters · filed 2017-05-22 | -$17.10M derived: sum of 3 quarters · filed 2017-05-22 | $19.60M 10-K · filed 2017-05-22 | |
| 2014-03-29 | $88.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | -$207.20M derived: sum of 2 quarters · filed 2015-04-29 | -$170.50M 10-Q · filed 2015-04-29 | $308.60M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2013-12-28 | -$295.50M derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05 | -$258.80M 10-Q · filed 2015-02-05 | $220.30M derived: sum of 3 quarters · filed 2016-02-25 | $61.60M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2013-09-28 | $36.70M 8-K · filed 2014-11-20 | $4.00 10-Q · filed 2013-11-04 | $515.80M derived: sum of 2 quarters · filed 2016-02-25 | $357.10M derived: sum of 3 quarters · filed 2016-02-25 | |
| 2013-06-29 | $479.10M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $320.40M derived: sum of 2 quarters · filed 2016-02-25 | $177.40M 10-KT · filed 2016-02-25 | ||
| 2013-03-30 | -$158.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | -$301.70M 10-Q · filed 2014-05-07 | |||
| 2012-12-29 | -$143.00M 10-Q · filed 2014-02-06 | ||||
| 2012-06-30 | $292.40M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |